Lacosamida Pentafarma (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilises hyper‑excitable neurons, reduces repetitive firing, and helps prevent the spread of seizure activity without significantly affecting normal neuronal function.

The specific dose of Lacosamida Pentafarma is determined by the prescribing clinician based on the patient’s age, renal and hepatic function, and response to therapy. Dosage regimens are individualized and should follow the prescriber’s instructions.

The pregnancy safety category for lacosamide is unknown. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Women who are breastfeeding should discuss possible exposure with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many older antiepileptics that target fast inactivation. This can provide additive seizure control when combined with other agents and may have a distinct side‑effect profile, such as lower risk of cognitive impairment compared with some alternatives.

Lacosamida Pentafarma should be stored at room temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

The medication is taken orally, usually as a tablet, with or without food. The exact timing and frequency are set by the prescriber, who may adjust the schedule based on therapeutic response and tolerability.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, potential suicidal thoughts or behaviors, severe skin reactions like Stevens‑Johnson syndrome, hypersensitivity reactions, and rare cases of rhabdomyolysis. Patients should be monitored for these events, especially during treatment initiation.

Patients with known hypersensitivity to lacosamide or any of its excipients should avoid the product. Caution is also advised for individuals with significant cardiac conduction disorders, severe renal or hepatic impairment, and those taking interacting medications that could markedly reduce efficacy.